Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More
Neurological biomarker research is advancing rapidly, but key challenges remain. Download this new Whitepaper from Olink entitled ‘Navigating neurological biomarker research: Progress, learnings and future directions’. The Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A… Read More
Neurological biomarker research is advancing rapidly, but key challenges remain. This Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Read More
Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More
Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More
Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More
The tumour microenvironment (TME) is no longer considered a passive backdrop to cancer. It is a dynamic ecosystem that plays a central role in tumour growth, immune suppression, metastasis and treatment resistance. Whitepaper highlights: Understand how the TME drives cancer progression, immune evasion and therapeutic resistance Explore emerging strategies that… Read More
Aptamer Group has launched its biomarker discovery service, offering researchers in pharmaceutical, biotechnology, and diagnostic development a new approach to identify and validate new disease markers. The service integrates Aptamer’s Optimer technology with proteomic analysis to provide an unbiased, high-throughput approach to biomarker identification. This… Read More
The Global Neurodegeneration Proteomics Consortium (GNPC) has released research analyses of one of the world’s largest protein datasets in order offer new insights into the biological underpinnings of major neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The findings, published in a series of papers in Nature Medicine, reveal… Read More
Techbio Tailor Bio has published a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types. The study, carried out in collaboration with the University of Cambridge and the Spanish National Cancer… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “How biomarkers can help discover new treatments for women’s health” and… Read More
DDW’s Megan Thomas speaks with Dr Maria-Magdalena Patru, Scientific Partner at Roche Diagnostics US, about how advances in Alzheimer’s disease (AD), particularly blood-based biomarkers (BBM), can enable earlier, more accurate, and accessible detection of the disease, supporting timely treatment and improved patient outcomes. MT: Why is improving AD diagnostics crucial… Read More
This is the latest episode of the free DDW narrated podcast, titled “The far-reaching impact of drug discovery technology”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Accelerating time to market through digitalisation”, “… Read More
The US Food and Drug Administration (FDA) has approved Vyloy (zolbetuximab-clzb) for locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults… Read More
DDW Editor Reece Armstrong speaks to Alessio Travaglia, PhD, Director, Translational Science, Neuroscience, Foundation for the National Institutes of Health (FNIH) about challenges in treating amyotrophic lateral sclerosis (ALS) and why a new public-private partnership launched by the FNIH is hoping to advance new drugs and diagnostics for the… Read More
Software company Proscia has partnered with spatial AI biomarker company Nucleai in a collaboration aimed at improving precision medicine biomarkers for clinical trials. The companies are integrating Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and will make them available as part of Proscia’s precision medicine… Read More
